New York DOH grants RPCI approval to begin the genomic test patients with cancer -
Roswell Park Cancer Institute (RPCI) Approval The New York State Department of Health (DOH) has granted to begin the genomic test cancer patients using its test OmniSeq TargetTM advanced molecular diagnostic laboratory.
testing, approved through clinical laboratory evaluation program of the DOH (CLEP), is part of a global approach developed by RPCI Centre for personalized medicine for profiling and interpretation of the genetic information contained in the tumor tissues of cancer patients. OmniSeq TargetTM is one of three tests approved for use in New York State that use next-generation sequencing, and it is the only test to exclusively target mutations in action -. These changes for which targeted therapeutic approaches exist
OmniSeq TargetTM analyzes 23 genes associated with various cancer - such as ALK, EGFR, PTEN and KRAS RNA. The use of multiple genomic broadband technologies OmniSeq TargetTM detect specific genetic mutations, translocations and copy number changes, looking for alterations and specific aberrations that indicate specific forms or targeted molecular cancer characteristics. The test uses a double sequencing platform for mutation assays, using both sequencing platforms Ion Torrent and Illumina -. One approach that has unparalleled sensitivity and positive predictive value compared to typical single platform model
"This is a test cancer of the next generation that is both comprehensive and targeted, and n 'there is no other test like the market, "says Carl Morrison, MD, DVM, executive director of the Center for personalized medicine." this focus on mutations in action is what makes our approach and what makes this test as an important tool in the therapeutic treatment. When a doctor receives the results of our back tests, they will be able to apply this new information and adjust the treatment plan decision making patient to get the appropriate targeted therapy. "
Roswell Park Cancer Institute has also developed a software system that provides clinically relevant information OmniSeq TargetTM trials in reports that are part of the electronic health records of patients, doctors to make decisions faster and more informed treatment. the cancer center plans to incorporate OmniSeq TargetTM tests in the management of many patients from the third quarter of 2014.
"This test represents a major advance in the patient care, "said RPCI President and CEO Donald L direction. Trump, MD. "For years, the promise of genomic medicine has been largely theoretical and prospective part. OmniSeq TargetTM gives us the ability to identify for many cancer patients that the therapy will be most effective for an individual, sparing patients from having to take a drug that was never going to work for them . We can expect dramatic improvements in both outcomes and patient quality of life. "
EmoticonEmoticon